PO56 | EXTERNAL VALIDATION OF THE SAVED SCORE IN A CANADIAN REGIONAL CANCER CENTER COHORT: A REAL-WORLD ANALYSIS
A. Naassan, R. Fatima, M. Naassan, C. Chisholm | Lakeridge Health, R.S. McLaughlin Durham Regional Cancer Centre, Department of Oncology, Oshawa, ON, Canada
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Introduction. Venous thromboembolism (VTE) remains a significant complication in multiple myeloma patients receiving immunomodulatory drugs, with incidence rates of 3-26%. The SAVED score was developed to stratify VTE risk using readily available clinical variables. While initial validation demonstrated strong discriminatory ability in large academic centers, real-world performance in community cancer centers has not been characterized. This study aims to validate the SAVED score in a Canadian Regional Cancer Centre cohort.
Methods. We reviewed 182 multiple myeloma patients who began lenalidomide treatment between January 2013 and February 2025 at the Durham Regional Cancer Centre, with follow-up through January 2026. The SAVED score was calculated using age >80 years (+1), Asian ethnicity (-3), prior VTE (+3), surgery within 90 days (+2), and dexamethasone 120-160 mg monthly (+1) or >160 mg monthly (+2). Patients were classified as low risk (SAVED 0-1) or high risk (≥2). The main result was VTE during lenalidomide therapy, which was confirmed by imaging. Statistical analysis included the Fisher exact test, Kaplan-Meier survival analysis with the log-rank test, and ROC curve analysis. Sensitivity analyses excluded patients with prior VTE and tested alternative cutoffs (≥3).
Results. The median age was 79 years. Overall VTE rate was 12.6% (23/182). Low-risk patients (n=139, 76.4%) had a 5.8% VTE rate vs. 34.9% in high-risk patients (n=43, 23.6%). The odds ratio was 8.77 (95% CI 3.39-22.69, p<0.001). The SAVED score showed good discrimination, with an AUC of 0.735 (95% CI 0.611–0.849). Kaplan-Meier analysis showed clear separation (log-rank p<0.001), with median VTE-free survival of 943 days (2.6 years) in high-risk vs 2,703 days (7.4 years) in low-risk patients. Sensitivity analyses confirmed robustness: excluding prior VTE (n=162) yielded OR 8.73 (p<0.001); an alternative cutoff of ≥3 showed OR 6.88 (p<0.001).
Conclusions. The SAVED score successfully stratified VTE risk in our community cancer center cohort, with high-risk patients demonstrating a 9-fold increased odds of VTE and significantly shorter VTE-free survival. These results support SAVED score-guided thromboprophylaxis decisions in community practice settings where most myeloma patients receive care. Future work should focus on evaluating the impact of SAVED score-guided thromboprophylaxis on VTE reduction and the cost-effectiveness of risk-stratified approaches to thromboprophylaxis in the community cancer center setting.
Downloads
Citations
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- Società Italiana di Emostasi e Trombosi, PO22 | LONG-TERM ANTICOAGULANT THERAPY AND REDUCTION OF OVARIAN CANCER RECURRENCE: CLINICAL EVIDENCE OF A POTENTIAL ANTITUMOUR EFFECT , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO51 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF FACTOR XI-TARGETING MONOCLONAL ANTIBODIES SUPPORTS DURABLE ANTICOAGULANT COVERAGE AND TRANSLATIONAL DOSE AND REGIMEN SELECTION , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO06 | ACTIVATED PLATELETS INDUCE THE FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS VIA TOLL-LIKE RECEPTOR-4 AND P-SELECTIN GLYCOPROTEIN LIGAND-1 , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO62 | CLINICAL AND MOLECULAR DIAGNOSTIC CHALLENGES IN MYELOPROLIFERATIVE NEOPLASMS WITH LOW JAK2V617F ALLELIC BURDEN , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO07 | PLATELET INHIBITION BY THE NOVEL NITRIC OXIDE-DONOR NITROSOOXYPROPANOL , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO34 | INVESTIGATORS’ DECISIONS ON ANTICOAGULATION AFTER EXTENDED API-CAT TREATMENT FOR CANCER VENOUS THROMBOEMBOLISM , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO65 | OVARIC CANCER PRESENTING WITH COLD-AGGLUTININ MEDIATED HEMOLYTIC ANEMIA, PULMONARY THROMBOEMBOLISM AND DEEP VEIN THROMBOSIS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO01 | MELANOMA-DERIVED EXTRACELLULAR VESICLES DRIVE VON WILLEBRAND FACTOR–DEPENDENT THROMBOSIS AND METASTASIS , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
